280 related articles for article (PubMed ID: 33140519)
1. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR
Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519
[TBL] [Abstract][Full Text] [Related]
2. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
3. Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
Zalmai R; Hill LG; Loera LJ; Mosgrove Q; Brown C
J Am Pharm Assoc (2003); 2023; 63(5):1558-1565.e4. PubMed ID: 37331654
[TBL] [Abstract][Full Text] [Related]
4. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
[TBL] [Abstract][Full Text] [Related]
5. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
7. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
8. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
11. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.
Ling W; Amass L; Shoptaw S; Annon JJ; Hillhouse M; Babcock D; Brigham G; Harrer J; Reid M; Muir J; Buchan B; Orr D; Woody G; Krejci J; Ziedonis D;
Addiction; 2005 Aug; 100(8):1090-100. PubMed ID: 16042639
[TBL] [Abstract][Full Text] [Related]
12. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
[TBL] [Abstract][Full Text] [Related]
15. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
[TBL] [Abstract][Full Text] [Related]
16. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
[TBL] [Abstract][Full Text] [Related]
17. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR
J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
Oller DA; Thornton C; Nuzzo PA; Fanucchi LC
J Addict Med; 2021 May-Jun 01; 15(3):187-190. PubMed ID: 32909986
[TBL] [Abstract][Full Text] [Related]
19. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.
Guadamuz JS; Alexander GC; Chaudhri T; Trotzky-Sirr R; Qato DM
JAMA Netw Open; 2019 Jun; 2(6):e195388. PubMed ID: 31173125
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
